IntraBio Inc., a global biopharmaceutical company focused on developing and commercializing therapies for neurological diseases, today announced that the U.S. Food and Drug Administration (FDA) has ...
Stock Surges Following Positive Clinical UpdateShares of Design Therapeutics (NASDAQ:DSGN) climbed 27% on Monday after the ...
Shares of Design Therapeutics jumped after the company reported positive data from a study of its DT-216P2 drug for Friedreich ataxia, a neuromuscular disease. The stock rose 10% to $15.85 in ...
Design Therapeutics Inc. DSGN stock surged during the premarket session on Monday. The move came after the company reported ...
Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, will announce data from the ongoing Phase 1/2 ...
Researchers have uncovered a fundamental rule that governs how genes are physically arranged inside the cell nucleus, and how ...
Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal ...
Families, campaigners and clinicians are calling for more public money to be provided to pay for access to drugs which could ...
Design Therapeutics, Inc. (NASDAQ:DSGN) was among Jim Cramer’s Mad Money stock calls as he urged investors to exercise ...
Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, will announce data from the ongoing ...
Novo Nordisk and Biogen are underpriced and stand to gain from new indications for their blockbuster therapies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results